Floatz logo

Bms-907351

Uterine Corpus Carcinosarcoma

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Uterine Corpus Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Metformin
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
Doxycycline
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
Tislelizumab
Floor Backes, MD
Early Phase 1C
Carboplatin
Floor Backes, MD
Early Phase 1C

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →